Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …

Abstract PET using 18 F-FDG for treatment monitoring in patients with lymphoma is one of
the most well-developed clinical applications. PET/CT is nowadays used during treatment to …

Purpose Recent advances in imaging, use of prognostic indices, and molecular profiling
techniques have the potential to improve disease characterization and outcomes in …

Background Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin …

Purpose Interim positron emission tomography (PET) using the tracer,[18F]
fluorodeoxyglucose, may predict outcomes in patients with aggressive non-Hodgkin …

Background The study objectives were to assess the prognostic value of quantitative PET
and to test whether combining baseline metabolic tumour burden with early PET response …

Since its introduction in the early nineties as a promising functional imaging technique in the
management of neoplastic disorders, FDG-PET, and subsequently FDG-PET/CT, has …

Background The outcome of diffuse large B-cell lymphoma has been substantially improved
by the addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy regimens …

Purpose To prospectively assess the clinical impact of expert review of lymphoma diagnosis
in France. Materials and Methods From January 2010 to December 2013, 42,145 samples …

Purpose R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and
prednisone) is standard care for aggressive B-cell lymphoma. A prospective trial was …